WeVote
Log In

Bill

YA

Bill

HR 6166

Lowering Drug Costs for American Families Act

119th Congress Introduced by Yassamin Ansari and 50 co-sponsors

HR 6166 reduces prescription drug costs for American families through price controls and negotiation mechanisms, with broad healthcare system implications under committee review.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 6166

Legislative bill overview

HR 6166 aims to reduce prescription drug costs for American families through mechanisms that likely include price negotiation authority, capping out-of-pocket expenses, or increasing generic drug availability. The bill was introduced in November 2025 and referred to three House committees with jurisdiction over healthcare, taxes, and labor issues, suggesting a comprehensive approach to drug pricing reform.

Why is this important

Prescription drug costs remain a significant financial burden for millions of Americans, with many rationing medications or skipping doses due to expense. Any successful drug cost reduction could improve healthcare access and outcomes while affecting federal spending, pharmaceutical industry revenue, and insurance premiums across the healthcare system.

Potential points of contention

  • Pharmaceutical industry impact: Drug manufacturers may argue that price controls reduce incentives for research and development of new treatments
  • Implementation complexity: Determining appropriate price points and enforcement mechanisms while maintaining market functionality presents significant technical challenges
  • Unintended consequences: Critics worry that aggressive cost controls could limit drug availability, reduce profit margins for pharmacies, or shift costs to other healthcare services

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.